Lilly Bamlanivimab Antibody Playbook
This antibody playbook provides information for state, territorial and local public health programs to plan and operationalize a bamlanivimab antibody response to COVID-19. The sections of this document cover specific areas of COVID-19 antibody program planning and implementation, as well as links to resources to assist with those efforts.
Related Content
Summary of Laboratory Developed Tests Final Rule
CHA Submits Energy and Commerce Committee Statement on Oversight of the 340B Drug Pricing Program
Addressing Pediatric Drug and Supply Shortages
Summary of Laboratory Developed Tests Final Rule
Children's Hospital Association sent a letter to Energy and Commerce leaders supporting pediatric-focused legislation included in a recent markup.
CHA Submits Energy and Commerce Committee Statement on Oversight of the 340B Drug Pricing Program
Children's Hospital Association urges the committee to work with provider stakeholders to enhance the effectiveness and integrity of the program for children's health.
Addressing Pediatric Drug and Supply Shortages
Children’s hospitals depend on a reliable and safe drug and supply chain to provide life-saving treatments to their pediatric patients.
